Patients that are scheduled for elective major hepatectomy due to liver tumors Major hepatectomy, Ursodeoxycholic acid (UDCA), Liver regeneration
Conditions
Interventions
The UDCA group will receive oral pretreatment of UDCA for two weeks preoperatively, a dosage of 15mg/kg/day in 3 divided doses. And postoperatively, the patients will continue to receive the UDCA for
Active Comparator Drug,Placebo Comparator Drug
The UDCA group ,Placebo group
Sponsors
Research Fund of Faculty of Medicine, Chiang Mai University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Age over 18 years 2. Elective major hepatectomy due to liver tumors 3. ICG R-15 less than 10% Obstructive jaundice case: TB < 3 mg/dL 4.Written informed consent
Exclusion criteria
Exclusion criteria: 1. Presence of medical conditions putting the individual patient at increased risk for not tolerating hepatic resection - Liver cirrhosis Child-Pugh B or C - ICG-R 15 more than 10% - Platelet less than 150,000 cells/cu.mm - Coagulopathy: INR > 1.5 2. Hypersensitivity to Ursodeoxycholic acid (UDCA) 3. Hypersensitivity to contrast media 4. Participation in other clinical trials or observation period of competing trials interfering with the endpoints of this trial 5. Suspected lack of compliance 6. Impaired mental status or language problems 7. Refusal to take part in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| liver regeneration 3 month 1. liver volume measurement from CT scan 2. Proinflammatory cytokines level 3. Histochemistry measurement | — |
Secondary
| Measure | Time frame |
|---|---|
| Post-hepatectomy liver failure 30 days Number of events (PHLF, 30-day mortality) | — |
Countries
Thailand
Contacts
Public ContactNutthida Kritwisarut
Faculty of Medicine, Chiang Mai University, Thailand
Outcome results
None listed